|
Gene: CD82 |
Gene summary for CD82 |
Gene summary. |
Gene information | Species | Human | Gene symbol | CD82 | Gene ID | 3732 |
Gene name | CD82 molecule | |
Gene Alias | 4F9 | |
Cytomap | 11p11.2 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | P27701 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3732 | CD82 | HTA11_2487_2000001011 | Human | Colorectum | SER | 9.79e-15 | 5.70e-01 | -0.1808 |
3732 | CD82 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.65e-09 | 4.68e-01 | -0.0811 |
3732 | CD82 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.36e-03 | 2.46e-01 | -0.1088 |
3732 | CD82 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.88e-06 | 2.49e-01 | -0.1954 |
3732 | CD82 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.78e-12 | 1.25e+00 | -0.2602 |
3732 | CD82 | HTA11_2112_2000001011 | Human | Colorectum | SER | 6.10e-09 | 7.60e-01 | -0.2196 |
3732 | CD82 | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.02e-02 | 2.51e-01 | -0.1207 |
3732 | CD82 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.91e-06 | 4.07e-01 | -0.1526 |
3732 | CD82 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.68e-13 | 3.53e-01 | -0.1464 |
3732 | CD82 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.19e-02 | 1.14e-01 | -0.1001 |
3732 | CD82 | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.52e-14 | 4.25e-01 | -0.059 |
3732 | CD82 | HTA11_546_2000001011 | Human | Colorectum | AD | 1.08e-02 | 2.74e-01 | -0.0842 |
3732 | CD82 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.78e-03 | 1.75e-01 | 0.096 |
3732 | CD82 | HTA11_8622_2000001021 | Human | Colorectum | SER | 4.25e-10 | 4.68e-01 | 0.0528 |
3732 | CD82 | HTA11_7663_2000001011 | Human | Colorectum | SER | 3.52e-02 | 3.95e-01 | 0.0131 |
3732 | CD82 | HTA11_6801_2000001011 | Human | Colorectum | SER | 4.59e-03 | 4.38e-01 | 0.0171 |
3732 | CD82 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.50e-07 | 3.37e-01 | 0.0338 |
3732 | CD82 | HTA11_7696_3000711011 | Human | Colorectum | AD | 6.09e-09 | 2.63e-01 | 0.0674 |
3732 | CD82 | HTA11_6818_2000001011 | Human | Colorectum | AD | 5.18e-03 | 4.45e-01 | 0.0112 |
3732 | CD82 | HTA11_6818_2000001021 | Human | Colorectum | AD | 4.82e-07 | 2.63e-01 | 0.0588 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | |
Skin | AK | |
Skin | SCCIS | |
Skin | cSCC | |
Thyroid | HT |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0411524 | Esophagus | ESCC | p53 signaling pathway | 65/4205 | 74/8465 | 3.88e-12 | 6.50e-11 | 3.33e-11 | 65 |
hsa0411534 | Esophagus | ESCC | p53 signaling pathway | 65/4205 | 74/8465 | 3.88e-12 | 6.50e-11 | 3.33e-11 | 65 |
hsa041156 | Liver | HCC | p53 signaling pathway | 46/4020 | 74/8465 | 7.64e-03 | 2.08e-02 | 1.16e-02 | 46 |
hsa0411511 | Liver | HCC | p53 signaling pathway | 46/4020 | 74/8465 | 7.64e-03 | 2.08e-02 | 1.16e-02 | 46 |
hsa041159 | Oral cavity | OSCC | p53 signaling pathway | 57/3704 | 74/8465 | 4.99e-09 | 5.07e-08 | 2.58e-08 | 57 |
hsa0411514 | Oral cavity | OSCC | p53 signaling pathway | 57/3704 | 74/8465 | 4.99e-09 | 5.07e-08 | 2.58e-08 | 57 |
hsa0411523 | Oral cavity | LP | p53 signaling pathway | 38/2418 | 74/8465 | 2.82e-05 | 1.92e-04 | 1.24e-04 | 38 |
hsa0411533 | Oral cavity | LP | p53 signaling pathway | 38/2418 | 74/8465 | 2.82e-05 | 1.92e-04 | 1.24e-04 | 38 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD82 | SNV | Missense_Mutation | c.240N>C | p.Glu80Asp | p.E80D | P27701 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-A6-6140-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | SD | |
CD82 | SNV | Missense_Mutation | novel | c.692N>C | p.Ile231Thr | p.I231T | P27701 | protein_coding | deleterious(0) | possibly_damaging(0.828) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CD82 | SNV | Missense_Mutation | rs766230830 | c.775N>A | p.Glu259Lys | p.E259K | P27701 | protein_coding | deleterious(0.04) | possibly_damaging(0.799) | TCGA-AJ-A3OL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
CD82 | SNV | Missense_Mutation | c.664N>A | p.Ala222Thr | p.A222T | P27701 | protein_coding | tolerated(0.42) | benign(0.02) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CD82 | SNV | Missense_Mutation | rs761257124 | c.37N>A | p.Leu13Ile | p.L13I | P27701 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
CD82 | SNV | Missense_Mutation | novel | c.163N>A | p.Gly55Arg | p.G55R | P27701 | protein_coding | deleterious(0.03) | probably_damaging(0.978) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CD82 | SNV | Missense_Mutation | c.304N>A | p.Ala102Thr | p.A102T | P27701 | protein_coding | tolerated(0.12) | possibly_damaging(0.554) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CD82 | SNV | Missense_Mutation | novel | c.547N>A | p.Asp183Asn | p.D183N | P27701 | protein_coding | tolerated(0.94) | possibly_damaging(0.494) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CD82 | SNV | Missense_Mutation | c.502C>T | p.Pro168Ser | p.P168S | P27701 | protein_coding | tolerated(1) | benign(0) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CD82 | SNV | Missense_Mutation | novel | c.682N>A | p.Leu228Met | p.L228M | P27701 | protein_coding | deleterious(0.02) | possibly_damaging(0.844) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3732 | CD82 | DRUGGABLE GENOME, CELL SURFACE | NERVE GROWTH FACTOR | 10353759 |
Page: 1 |